Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K. (October 2022) - Kalinsky, K.; Zihan, W.; McCourt, C.; Mitchell, E.P.; Wright, J.J.; Doyle, L.A.; Gray, R.J.; Wang, V.; McShane, L.M.; Rubinstein, L.V.; Patton, D.; Williams, P.M.; et al.